The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study

Dilated Cardiomyopathy (DCM) Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00523653
• Other study ID #: BMB 07-004
• Status: Recruiting
• Phase: N/A
• First received: August 29, 2007
• Last updated: March 17, 2008
• Start date: January 2008
• Est. completion date: December 2008

Study information

• Verified date: March 2008
• Source: McGill University Health Center
• Contact: Nadia S Giannetti, MD
• Phone: (514)934 1934
• Email: nadia.giannetti[@]much.mcgill.ca
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Observational

Clinical Trial Summary

Dilated cardiomyopathy (DCM) affects about 200,000 Canadians. Eighty percent of these cases are of unclear cause, often occuring in families. We believe that mutations in specific already-identified genes contribute to DCM in Quebec and that certain mutations may account for a significant proportion of cases due to the well-documented "founder effect". Two hundred patients with DCM followed in our Heart Function Clinic will be approached for one blood sample at their routine clinic visit to test this hypothesis. The samples will be tested in the Laboratory of Cardiovascular Genetics at the Royal Victoria Hospital.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Followed at MUHC Heart Function Centre

• Documented EF of less than or equal to 35% and an enlarged heart with a left ventricular end-diastolic size of greater than 6 cm.

• Patient's written consent

Exclusion Criteria:

• Patients with a known underlying condition that results in a weakened and enlarged heart

• Patients unable to read and understand the consent form

• Patients who do not wish to participate

Study Design

Observational Model: Family-Based, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Dilated
• Dilated Cardiomyopathy (DCM)

Intervention

Other:
• blood test
looking at DNA

Locations

Country	Name	City	State
Canada	Royal Victoria Hospital	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
McGill University Health Center

Country where clinical trial is conducted

Canada,